COMP <GO>
MDXG vs LLY // OPERATING MARGIN
MiMedx Group Inc (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: MDXG 4
— LLY 8
▲ OPERATING MARGIN LEADER: LLY
LAST: $3.97 (+0.51%) • MKT CAP: $579.3M
operating-margins
15.30%
LAST: $1,373.70 (+6.63%) • MKT CAP: $1.29T
operating-margins
40.21%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MDXG VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MDXG | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 82.60% | 83.64% | -1.04 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 47.20% | 32.36% | +14.84 | MDXG | /roic <GO> |
| EV/EBITDA & P/E Valuation | 6.7x | 36.4x | -29.72 | MDXG | /valuation <GO> |
| Free Cash Flow Yield | 12.77% | 2.30% | +10.47 | MDXG | /fcf-yield <GO> |
| Operating Margin ACTIVE | 15.30% | 40.21% | -24.91 | LLY | /operating-margins <GO> |
| Net Profit Margin | 11.60% | 31.90% | -20.30 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 20.00% | 45.51% | -25.51 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 6.45 | 9.29 | -2.84 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 9/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.77% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 32.9 | 66.6 | -33.73 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.51 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 10.0x | 26.3x | -16.25 | MDXG | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $579.3M | $1.29T | -$1.29T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MDXG REV | LLY REV | MDXG GROSS % | LLY GROSS % | MDXG FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $418.6M | $65.18B | 82.6% | 83.0% | $74.0M | $16.81B |
| FY 2024 | $348.9M | $45.04B | 82.8% | 81.3% | $66.2M | $8.82B |
| FY 2023 | $321.5M | $34.12B | — | 79.3% | $26.8M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MDXG // BETA —
LLY // BETA 0.51